# Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms

Source: https://onco.cc/trials/nct00004688/  
OnCo record `nct00004688` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Carmustine, Mercaptopurine and Streptozocin in Oligodendroglioma, IDH-mutant and 1p/19q-codeleted and Glioma & glioblastoma, run by Emory University, completed.

## Summary

Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms is a phase 2 interventional study registered as NCT00004688 by Emory University, with 35 participants recorded, started 1996-08. Interventions recorded: carmustine, mercaptopurine, streptozocin. Conditions recorded: Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Mixed Gliomas, Glioblastoma Multiforme, Recurrent Brain Tumor.

Linked to the drug Streptozocin because the registry names it among its interventions and Oligodendroglioma, IDH-mutant and 1p/19q-codeleted and Glioma & glioblastoma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT00004688
- Phase: 2
- Setting: Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms
- Sponsor: Emory University
- Enrolled: 35

## Sources

- ClinicalTrials.gov NCT00004688: https://clinicaltrials.gov/study/NCT00004688

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/), [Oligodendroglioma, IDH-mutant and 1p/19q-codeleted](https://onco.cc/cancers/oligodendroglioma/)
- drugs: [Carmustine](https://onco.cc/drugs/carmustine/), [Mercaptopurine](https://onco.cc/drugs/mercaptopurine/), [Streptozocin](https://onco.cc/drugs/streptozocin/)

---
JSON: https://onco.cc/api/v1/entities/nct00004688.json